SERPINC1 (antithrombin) · GalNAc, SC
Fitusiran (Qfitlia)
An approved siRNA therapeutic silencing SERPINC1 (antithrombin), indicated for Hemophilia A/B. This page lists what the siRNA Atlas corpus holds on Fitusiran and links to each primary document.
Identity
- Generic name
- Fitusiran
- Brand name
- Qfitlia
- Molecular target
- SERPINC1 (antithrombin)
- Indication
- Hemophilia A/B
- Delivery
- GalNAc, SC
- FDA application
- NDA 219019
- Regulatory coverage
- FDA only
Source documents in the corpus (2)
Every answer about Fitusiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Fitusiran
- →What is the approved dose and dosing interval of fitusiran (Qfitlia)?
- →Describe the clinical pharmacology and ADME of fitusiran.
- →What did the regulatory reviews conclude about the nonclinical safety of fitusiran?
- →Summarise the pivotal trial evidence for fitusiran.
- →How does fitusiran silence SERPINC1 (antithrombin), and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.